Literature DB >> 15849724

Risk factors for pancreatic cancer.

Albert B Lowenfels1, Patrick Maisonneuve.   

Abstract

In the United States, the cumulative mortality or lifetime risk of dying from pancreatic cancer is about 1-2%, but although this form of cancer is rare, nearly all patients die from the disease within one to two years. Because of its lethality, pancreatic cancer now ranks fourth as a cause of death from cancer. There are country-specific differences in rates, perhaps explained by differences in life-style factors or diet. African-Americans in the USA have rates that are about 50% higher than Caucasians. Smoking is the major known risk factor for this cancer, explaining 20-30% of all cases. Another 5-10% of causes are caused by germline mutations, with mutations in BRCA2 being the most frequent. Two background diseases increase the risk of pancreatic cancer-pancreatitis, and diabetes. Major challenges presented by this cancer are: 1) determination of the molecular pathways that make this cancer so aggressive; 2) development of new modalities, perhaps based on proteomics, to enhance early detection.

Entities:  

Mesh:

Year:  2005        PMID: 15849724     DOI: 10.1002/jcb.20461

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  55 in total

1.  Mutations in Fanconi anemia genes and the risk of esophageal cancer.

Authors:  Mohammad R Akbari; Reza Malekzadeh; Pierre Lepage; David Roquis; Ali R Sadjadi; Karim Aghcheli; Abbas Yazdanbod; Ramin Shakeri; Jafar Bashiri; Masoud Sotoudeh; Akram Pourshams; Parviz Ghadirian; Steven A Narod
Journal:  Hum Genet       Date:  2011-01-30       Impact factor: 4.132

2.  Human pancreas-specific protein disulfide isomerase homolog (PDIp) is an intracellular estrogen-binding protein that modulates estrogen levels and actions in target cells.

Authors:  Xin-Miao Fu; Bao Ting Zhu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-02-21       Impact factor: 4.292

Review 3.  The pathobiological impact of cigarette smoke on pancreatic cancer development (review).

Authors:  Uwe A Wittel; Navneet Momi; Gabriel Seifert; Thorsten Wiech; Ulrich T Hopt; Surinder K Batra
Journal:  Int J Oncol       Date:  2012-03-23       Impact factor: 5.650

Review 4.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Beta-adrenergic signaling in the development and progression of pulmonary and pancreatic adenocarcinoma.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei
Journal:  Curr Cancer Ther Rev       Date:  2012-05-01

Review 6.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

7.  Risk factors for pancreatic cancer: case-control study.

Authors:  Manal M Hassan; Melissa L Bondy; Robert A Wolff; James L Abbruzzese; Jean-Nicolas Vauthey; Peter W Pisters; Douglas B Evans; Rabia Khan; Ta-Hsu Chou; Renato Lenzi; Li Jiao; Donghui Li
Journal:  Am J Gastroenterol       Date:  2007-08-31       Impact factor: 10.864

Review 8.  [Hereditary pancreatic cancer].

Authors:  N Habbe; P Langer; D K Bartsch
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

9.  Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.

Authors:  Jun Gao; Jian Song; Haojie Huang; Zhaoshen Li; Yiqi Du; Jia Cao; Minghui Li; Shunli Lv; Han Lin; Yanfang Gong
Journal:  J Exp Clin Cancer Res       Date:  2010-03-26

10.  Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells.

Authors:  Galina Chipitsyna; Qiaoke Gong; Rathai Anandanadesan; Amer Alnajar; Surinder K Batra; Uwe A Wittel; Diane M Cullen; Mohammed P Akhter; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.